T1 Mapping and Extracellular Volume in Cardiomyopathy Showing Left Ventricular Hypertrophy: Differentiation Between Hypertrophic Cardiomyopathy and Hypertensive Heart Disease

References

• Wang C, Zheng J, Sun J, et al. Endogenous contrast T1rho cardiac magnetic resonance for myocardial fibrosis in hypertrophic cardiomyopathy patients. J Cardiol. 2015;66:520–526. doi:10.1016/j.jjcc.2015.03.005
   PubMed Web of Science ®Google Scholar
• Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6:587–596. doi:10.1016/j.jcmg.2012.09.018
   PubMed Web of Science ®Google Scholar
• St JSM, Lie JT, Anderson KR, O’Brien PC, Frye RL. Histopathological specificity of hypertrophic obstructive cardiomyopathy. Myocardial fibre disarray and myocardial fibrosis. Br Heart J. 1980;44:433–443. doi:10.1136/hrt.44.4.433
   PubMedGoogle Scholar
• Baxi AJ, Restrepo CS, Vargas D, Marmol-Velez A, Ocazionez D, Murillo H. Hypertrophic cardiomyopathy from A to Z: genetics, pathophysiology, imaging, and management. Radiographics. 2016;36:335–354. doi:10.1148/rg.2016150137
   PubMed Web of Science ®Google Scholar
• Zhou H, Lin X, Fang L, et al. Characterization of compacted myocardial abnormalities by cardiac magnetic resonance with native T1 mapping in left ventricular non-compaction patients- a comparison with late gadolinium enhancement. Circ J. 2016;80:1210–1216. doi:10.1253/circj.CJ-15-1269
   PubMed Web of Science ®Google Scholar
• Ikeda U, Minamisawa M, Koyama J. Isolated left ventricular non-compaction cardiomyopathy in adults. J Cardiol. 2015;65:91–97. doi:10.1016/j.jjcc.2014.10.005
   PubMed Web of Science ®Google Scholar
• Garg P, Saunders LC, Swift AJ, Wild JM, Plein S. Role of cardiac T1 mapping and extracellular volume in the assessment of myocardial infarction. Anatol J Cardiol. 2018;19:404–411. doi:10.14744/AnatolJCardiol.2018.39586
   PubMed Web of Science ®Google Scholar
• Dual SA, Maforo NG, McElhinney DB, et al. Right ventricular function and T1-mapping in boys with Duchenne muscular dystrophy. J Magn Reson Imaging. 2021;54:1503–1513. doi:10.1002/jmri.27729
   PubMed Web of Science ®Google Scholar
• Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552–563. doi:10.1056/NEJMoa1002659
   PubMed Web of Science ®Google Scholar
• Hinojar R, Varma N, Child N, et al. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2015;8:45.
   Web of Science ®Google Scholar
• Dabir D, Child N, Kalra A, et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2014;16:69. doi:10.1186/s12968-014-0069-x
   PubMed Web of Science ®Google Scholar
• Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270–276. doi:10.1093/eurheartj/ehm342
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–1566. doi:10.1056/NEJM199005313222203
   PubMed Web of Science ®Google Scholar
• Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–2779.
   PubMed Web of Science ®Google Scholar
• Ellims AH, Iles LM, Ling LH, et al. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype. Eur Heart J Cardiovasc Imaging. 2014;15:1108–1116. doi:10.1093/ehjci/jeu077
   PubMed Web of Science ®Google Scholar
• Hinojar R, Botnar R, Kaski JC, Prasad S, Nagel E, Puntmann VO. Individualized cardiovascular risk assessment by cardiovascular magnetic resonance. Future Cardiol. 2014;10:273–289. doi:10.2217/fca.13.102
   PubMedGoogle Scholar
• Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407–1424. doi:10.1016/j.jacc.2009.04.094
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206–1216. doi:10.1161/CIRCULATIONAHA.111.089409
   PubMed Web of Science ®Google Scholar
• Klem I, Shah DJ, White RD, et al. Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ Cardiovasc Imaging. 2011;4:610–619. doi:10.1161/CIRCIMAGING.111.964965
   PubMed Web of Science ®Google Scholar
• Ho CY, Abbasi SA, Neilan TG, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6:415–422. doi:10.1161/CIRCIMAGING.112.000333
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6:475–484. doi:10.1016/j.jcmg.2012.08.019
   PubMed Web of Science ®Google Scholar
• Sado DM, Flett AS, Banypersad SM, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436–1441. doi:10.1136/heartjnl-2012-302346
   PubMed Web of Science ®Google Scholar
• Brouwer WP, Baars EN, Germans T, et al. In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:28. doi:10.1186/1532-429X-16-28
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017;19:75.
   PubMed Web of Science ®Google Scholar
• Anversa P, Palackal T, Sonnenblick EH, Olivetti G, Capasso JM. Hypertensive cardiomyopathy. Myocyte nuclei hyperplasia in the mammalian rat heart. J Clin Invest. 1990;85:994–997. doi:10.1172/JCI114576
   PubMed Web of Science ®Google Scholar
• Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess. Prevention of scarring by amiloride. Am J Hypertens. 1993;6:487–495. doi:10.1093/ajh/6.6.487
   PubMed Web of Science ®Google Scholar
• Schelbert EB, Wong TC, Gheorghiade M. Think small and examine the constituents of left ventricular hypertrophy and heart failure: cardiomyocytes versus fibroblasts, collagen, and capillaries in the interstitium. J Am Heart Assoc. 2015;4:e2491. doi:10.1161/JAHA.115.002491
   Web of Science ®Google Scholar